Literature DB >> 20607707

11q21.1-11q23.3 Is a site of intrinsic genomic instability triggered by irradiation.

Nga Du1, Pamela M Baker, To Uyen Do, Christine Bien, Carol M Bier-Laning, Sheetal Singh, Shyh-Jen Shih, Manual O Diaz, Andrew T Vaughan.   

Abstract

The chromosome location, 11q21-23, is linked to loss of heterozygosity (LOH) in multiple tumors including those of breast, lung, and head and neck. To examine the process of LOH induction, the H292 cell line (human muco-epidermoid carcinoma) was irradiated or treated with anti-CD95 antibody, and individual clones isolated through two rounds of cloning. Regions of LOH were determined by screening a suite of eight polymorphic microsatellite markers covering 11p15-11q24 using fluorescent primers and genetic analyzer peak discrimination. LOH induction was observed extending through 11q21.1-11q23.3 in 6/49 of clones surviving 4 Gy and 8/50 after 8 Gy. Analysis of selected clones by Affymetrix 6.0 single nucleotide polymorphism (SNP) arrays confirmed the initial assessment indicating a consistent 27.3-27.7 Mbp deletion in multiple clones. The telomeric border of LOH mapped to a 1 Mbp region of elevated recombination. Whole genome analysis of SNP data indicated that site-restricted LOH also occurred across multiple additional genomic locations. These data indicate that 11q21.1-11q23.3, and potentially other regions of this cell line are sites of intrinsic cell-specific instability leading to LOH after irradiation. Such deletions may subsequently be propagated by genetic selection and clonal expansion. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20607707      PMCID: PMC2921793          DOI: 10.1002/gcc.20791

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  46 in total

1.  Cis-acting modifiers of expanded CAG/CTG triplet repeat expandability: associations with flanking GC content and proximity to CpG islands.

Authors:  G J Brock; N H Anderson; D G Monckton
Journal:  Hum Mol Genet       Date:  1999-06       Impact factor: 6.150

2.  Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin.

Authors:  D P SLAUGHTER; H W SOUTHWICK; W SMEJKAL
Journal:  Cancer       Date:  1953-09       Impact factor: 6.860

3.  A high-resolution survey of deletion polymorphism in the human genome.

Authors:  Donald F Conrad; T Daniel Andrews; Nigel P Carter; Matthew E Hurles; Jonathan K Pritchard
Journal:  Nat Genet       Date:  2005-12-04       Impact factor: 38.330

4.  Increasing genomic instability during premalignant neoplastic progression revealed through high resolution array-CGH.

Authors:  Lisa A Lai; Thomas G Paulson; Xiaohong Li; Carissa A Sanchez; Carlo Maley; Robert D Odze; Brian J Reid; Peter S Rabinovitch
Journal:  Genes Chromosomes Cancer       Date:  2007-06       Impact factor: 5.006

5.  Transforming activity of MECT1-MAML2 fusion oncoprotein is mediated by constitutive CREB activation.

Authors:  Lizi Wu; Jingxuan Liu; Ping Gao; Makoto Nakamura; Yang Cao; Huangxuan Shen; James D Griffin
Journal:  EMBO J       Date:  2005-06-16       Impact factor: 11.598

6.  Suppression of replication fork progression in low-dose-specific p53-dependent S-phase DNA damage checkpoint.

Authors:  T Shimura; M Toyoshima; S K Adiga; T Kunoh; H Nagai; N Shimizu; M Inoue; O Niwa
Journal:  Oncogene       Date:  2006-05-08       Impact factor: 9.867

7.  Microenvironmental genomic alterations and clinicopathological behavior in head and neck squamous cell carcinoma.

Authors:  Frank Weber; Yaomin Xu; Li Zhang; Attila Patocs; Lei Shen; Petra Platzer; Charis Eng
Journal:  JAMA       Date:  2007-01-10       Impact factor: 56.272

8.  Fine mapping and evaluation of candidate genes for cervical cancer on 11q23.

Authors:  Zhengyan Zhang; Daniela S Gerhard; Loan Nguyen; Jianduan Li; Amber Traugott; Phyllis C Huettner; Janet S Rader
Journal:  Genes Chromosomes Cancer       Date:  2005-05       Impact factor: 5.006

9.  Tumor suppressor in lung cancer-1 (TSLC1) functions as a glioma tumor suppressor.

Authors:  S S Houshmandi; E I Surace; H B Zhang; G N Fuller; D H Gutmann
Journal:  Neurology       Date:  2006-11-28       Impact factor: 9.910

10.  Loss of TSLC1 expression in lung adenocarcinoma: relationships with histological subtypes, sex and prognostic significance.

Authors:  Akiteru Goto; Toshiro Niki; Li Chi-Pin; Daisuke Matsubara; Yoshinori Murakami; Nobuaki Funata; Masashi Fukayama
Journal:  Cancer Sci       Date:  2005-08       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.